Brainsway (BWAY) Projected to Post Earnings on Wednesday

Brainsway (NASDAQ:BWAY) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $14.0180 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 8:30 AM ET.

Brainsway Trading Down 2.2%

Shares of BWAY opened at $23.18 on Wednesday. The company has a market cap of $454.56 million, a price-to-earnings ratio of 77.27 and a beta of 1.20. The business’s fifty day simple moving average is $11.54 and its two-hundred day simple moving average is $9.24. Brainsway has a 12 month low of $7.84 and a 12 month high of $26.63.

Institutional Investors Weigh In On Brainsway

Several hedge funds and other institutional investors have recently modified their holdings of BWAY. NewEdge Advisors LLC lifted its position in Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after purchasing an additional 7,549 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Brainsway in the second quarter worth about $85,000. UBS Group AG lifted its position in shares of Brainsway by 2,028.6% during the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after buying an additional 60,877 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of Brainsway by 25.2% during the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after acquiring an additional 20,706 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Brainsway in the 3rd quarter worth approximately $107,000. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BWAY has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a research report on Monday, December 29th. Wall Street Zen cut shares of Brainsway from a “buy” rating to a “hold” rating in a research note on Friday, January 23rd. HC Wainwright lifted their price target on shares of Brainsway from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Northland Securities set a $15.00 price objective on shares of Brainsway in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.